Using nanoparticles to improve treatment for tuberculosis and HIV
Immunotherapeutic nanoparticles: Implications for the treatment of tuberculosis and HIV
This study is looking at a new way to help people with both tuberculosis and HIV by using tiny particles to deliver a medicine directly to their lungs, making it easier for their bodies to fight the infection while reducing side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10897977 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat tuberculosis (TB) in patients who are also living with HIV by using specially designed nanoparticles. These nanoparticles are engineered to deliver a drug called rifampin directly to immune cells in the lungs, enhancing the body's ability to fight off the infection. The study focuses on how effectively these nanoparticles can release the drug and stimulate the immune response over time. By targeting the delivery of medication, the goal is to reduce the side effects and improve the overall treatment regimen for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are at high risk of developing tuberculosis.
Not a fit: Patients who do not have HIV or tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less burdensome treatment options for patients with both tuberculosis and HIV.
How similar studies have performed: While targeted drug delivery methods are being explored in various contexts, this specific approach using nanoparticles for TB and HIV treatment is relatively novel.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Reynolds, Jessica L — State University of New York at Buffalo
- Study coordinator: Reynolds, Jessica L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.